← Human Trials & Peer-Reviewed Studies
Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
Plain-language guide to PMID 35582947 (2022): placebo-controlled randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 35582947
- Journal
- Stroke
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Strain WD et al. (9 authors)
- DOI
- 10.1161/STROKEAHA.121.037775
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Semaglutide.
SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes) and PIONEER 6 (Peptide Innovation for Early Diabetes Treatment) were randomized cardiovascular outcome trials of subcutaneous and oral semaglutide in people with type 2 diabetes at high cardiovascular risk, respectively.
Why It Was Studied
This post hoc analysis examined the subcutaneous and oral semaglutide effects, versus placebo, on stroke and its subtypes in people with type 2 diabetes at high cardiovascular risk.
Gov; Unique identifier: NCT01720446 and NCT02692716.
Who Took Part
The impact of prior stroke, prior myocardial infarction or stroke, age, sex, systolic blood pressure, estimated glomerular filtration rate, and prior atrial fibrillation on treatment effects was assessed using interaction P values.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
Risk of major adverse cardiovascular event was analyzed according to prior stroke.
What Was Measured
PubMed files the paper under topics including Atrial Fibrillation, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Stroke and Semaglutide.
The authors tagged it with the keywords blood pressure, myocardial infarction and prevalence.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Semaglutide.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Stroke), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.